SCHEMBL180986

SCHEMBL180986

Brc1cccnn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30828602 1.00
Bromide SCHEMBL14939493 0.97
Bromide SCHEMBL30543193 0.97
Bromide SCHEMBL28136604 0.95
SCHEMBL27694077 0.77 FAAH (0.40)
SCHEMBL131463 0.71
SCHEMBL1456807 0.69 GOT1 (0.46)
SCHEMBL30792004 0.69 GOT1 (0.46)
SCHEMBL29442588 0.69 GOT1 (0.46)
SCHEMBL28175343 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 717 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118955404-A Synthesis method of compound 3, 5-dibromopyridazine 凯美克(上海)医药科技有限公司 2024-11-15 CN claimed
CN-118271447-A Engineered hinge regions, antibodies, conjugates and methods of making the same 菲鹏生物股份有限公司 2024-07-02 CN claimed
CN-117946307-B Pyridazine resin, preparation method thereof and cobalt removal method of lithium battery recovery liquid 江苏海普功能材料有限公司 2024-06-07 CN claimed
CN-117946307-A Pyridazine resin, preparation method thereof and cobalt removal method of lithium battery recovery liquid 江苏海普功能材料有限公司 2024-04-30 CN claimed
EP-4743445-A1 NOVEL HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS DNA POLYMERASE THETA INHIBITORS FOR THE PREVENTION OR TREATMENT OF CANCER Daewoong Pharmaceutical Co., Ltd. (KR) 2026-05-20 EP disclosed
CN-122036731-A CB1 receptor inverse agonist compound, pharmaceutical composition, preparation method and application thereof 北京康辰药业股份有限公司 2026-05-15 CN disclosed
EP-4741392-A1 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF Shenzhen TargetRx Co., Ltd. (CN) 2026-05-13 EP disclosed
EP-4568746-B1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-04-29 EP disclosed
EP-4073062-B1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) RYVU THERAPEUTICS S A (PL) 2026-04-29 EP disclosed
EP-4720067-A1 BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY Recursion Pharmaceuticals, Inc. (US) 2026-04-08 EP disclosed
US-12595244-B2 Small molecule inhibitors of mammalian SLC6A19 function JNANA THERAPEUTICS INC. (US) 2026-04-07 US disclosed
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 US disclosed
EP-1177176-A1 TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS Aventis Pharma Deutschland GmbH (DE) 2002-02-06 EP disclosed
WO-2000064876-A1 TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-11-02 WO disclosed
US-6121266-A TREATMENT/PROPHYLAXIS OF INFLAMMATORY DISEASES, IMMUNE DISEASES, CANCER VERTEX PHARMACEUTICALS, INC. (US) 2000-09-19 US disclosed
EP-0628550-B1 Pyridazines as interleukin-1beta converting enzyme inhibitors SANOFI SA (FR) 1998-02-25 EP disclosed
US-5626791-A FERROELECTRIC LIQUID CRYSTALS HOECHST AKTIENGESELLSCHAFT (DE) 1997-05-06 US disclosed
EP-0628550-A2 Pyridazines as interleukin-1beta converting enzyme inhibitors STERLING WINTHROP INC. (US) 1994-12-14 EP disclosed
US-4686289-A Anisotropic compounds and liquid crystal mixtures MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1987-08-11 US disclosed
US-4622163-A Anisotropic compounds and liquid crystal mixtures MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1986-11-11 US disclosed